Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
46708-0567-30 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0567-90 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
78206-0147-01 78206-0147 trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous June 1, 2021 In Use
00069-1500-60 00069-1500 CRIZOTINIB Xalkori 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
59923-0721-60 59923-0721 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2020 In Use
64980-0276-06 64980-0276 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 1, 2017 In Use
65162-0843-06 65162-0843 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used
43598-0671-11 43598-0671 Fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 20, 2020 In Use
82448-0150-14 82448-0150 Nirogacestat OGSIVEO 150.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov. 27, 2023 In Use
00054-0271-21 00054-0271 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 15, 2016 In Use
31722-0774-60 31722-0774 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 5, 2024 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00597-0145-60 00597-0145 Nintedanib Ofev 150.0 mg/1, 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Oral Oct. 17, 2014 In Use
59572-0215-13 59572-0215 Thalidomide Thalomid 150.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 20, 2007 In Use
59572-0215-93 59572-0215 Thalidomide Thalomid 150.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 20, 2007 In Use
81864-0102-30 81864-0102 Momelotinib Ojjaara 150.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Sept. 15, 2023 In Use
51991-0892-33 51991-0892 Erlotinib Hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
69097-0949-03 69097-0949 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 1, 2023 In Use
00006-5033-02 00006-5033 Trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous April 15, 2020 Sept. 30, 2023 No Longer Used
00378-2511-91 00378-2511 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Aug. 8, 2014 Aug. 31, 2023 No Longer Used
62135-0783-60 62135-0783 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 16, 2023 In Use
82511-0001-15 82511-0001 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2022 In Use

Found 10,000 results in 15 milliseconds — Export these results